{"id":3727,"date":"2020-10-01T11:43:29","date_gmt":"2020-10-01T10:43:29","guid":{"rendered":"https:\/\/www.ab-science.com\/sclerose-laterale-amyotrophique\/"},"modified":"2025-05-21T14:11:52","modified_gmt":"2025-05-21T13:11:52","slug":"sclerose-laterale-amyotrophique","status":"publish","type":"page","link":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/sclerose-laterale-amyotrophique\/","title":{"rendered":"Scl\u00e9rose Lat\u00e9rale Amyotrophique"},"content":{"rendered":"

[vc_row css=\u00a0\u00bb.vc_custom_1633514202311{background-color: #00477a !important;border: 10px solid #00477a !important;border-radius: 10px !important;}\u00a0\u00bb][vc_column css=\u00a0\u00bb.vc_custom_1633514590586{padding-top: 20px !important;}\u00a0\u00bb][vc_column_text css=\u00a0\u00bb.vc_custom_1633514499321{margin-bottom: 20px !important;}\u00a0\u00bb]<\/p>\n

Si vous souhaitez participer \u00e0 l\u2019\u00e9tude en cours, veuillez nous contacter \u00e0 clinical@ab-science.com<\/a>\u200b<\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column]

<\/span>\u00c0 propos de la Scl\u00e9rose Lat\u00e9rale Amyotrophique<\/span><\/div><\/div>
<\/div>[vc_column_text]La scl\u00e9rose lat\u00e9rale amyotrophique (SLA) est une maladie neurod\u00e9g\u00e9n\u00e9rative rare et potentiellement mortelle, caract\u00e9ris\u00e9e par une paralysie musculaire progressive refl\u00e9tant une d\u00e9g\u00e9n\u00e9rescence des neurones moteurs. La SLA est associ\u00e9e \u00e0 une morbidit\u00e9 importante et a de graves r\u00e9percussions sur le fonctionnement quotidien. La maladie est implacablement progressive.<\/p>\n

Il existe toujours un fort besoin de nouveaux traitements pour la SLA. En Europe, aucun m\u00e9dicament n’a \u00e9t\u00e9 enregistr\u00e9 depuis le riluzole, il y a 32 ans.[\/vc_column_text]

<\/span>Positionnement du masitinib dans la Scl\u00e9rose Lat\u00e9rale Amyotrophique<\/span><\/div><\/div>
<\/div>[vc_column_text]Le masitinib est actuellement le seul inhibiteur de la tyrosine kinase en phase avanc\u00e9e de d\u00e9veloppement pour la SLA. Le masitinib se distingue des autres m\u00e9dicaments dans le d\u00e9veloppement de la SLA en exer\u00e7ant une neuroprotection dans les syst\u00e8mes nerveux central et p\u00e9riph\u00e9rique.<\/p>\n

Le masitinib apparait comme unique parmi les autres m\u00e9dicaments utilis\u00e9s dans le d\u00e9veloppement de la SLA, car il exerce une neuroprotection \u00e0 la fois dans le syst\u00e8me nerveux central et dans le syst\u00e8me nerveux p\u00e9riph\u00e9rique par l\u2019inhibition s\u00e9lective des kinases qui modulent la fonctionnalit\u00e9 des diff\u00e9rentes cellules impliqu\u00e9es dans la pathogen\u00e8se de la SLA.<\/p>\n

En reconnaissance du besoin critique de nouveaux traitements, le masitinib a re\u00e7u la d\u00e9signation de m\u00e9dicament orphelin pour la SLA \u00e0 la fois de l\u2019Agence Europ\u00e9enne du M\u00e9dicament (EMA) et de la Food and Drug Administration (FDA) des \u00c9tats-Unis.[\/vc_column_text]

<\/div>
<\/span>R\u00e9sultats positifs de phase 2B\/3 du masitinib dans la Scl\u00e9rose Lat\u00e9rale Amyotrophique<\/span><\/div><\/div>
<\/div>[vc_column_text]AB Science a rapport\u00e9 des r\u00e9sultats positifs de phase 2B\/3 avec le masitinib dans la SLA. Dans cette \u00e9tude, le masitinib en association avec le riluzole a permis de retarder de mani\u00e8re significative (-27%) la progression de la maladie chez les patients atteints de SLA identifi\u00e9s comme progressant normalement, ce qui constituait la population de l’analyse primaire (c’est-\u00e0-dire les patients dont la progression de l’ALSFRS-R au d\u00e9part \u00e9tait <1,1 point\/mois).[\/vc_column_text][vc_column_text css=\u00a0\u00bb.vc_custom_1604232480025{margin-bottom: 0px !important;padding-bottom: 0px !important;}\u00a0\u00bb]<\/p>\n

Analyse primaire – \u00c9volution du score ALSFRS par rapport au niveau de r\u00e9f\u00e9rence<\/p>\n

[\/vc_column_text][vc_row_inner][vc_column_inner width=\u00a0\u00bb1\/6″][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb2\/3″][vc_single_image image=\u00a0\u00bb2487″ img_size=\u00a0\u00bbfull\u00a0\u00bb css_animation=\u00a0\u00bbfadeIn\u00a0\u00bb][\/vc_column_inner][vc_column_inner width=\u00a0\u00bb1\/6″][\/vc_column_inner][\/vc_row_inner][vc_column_text css=\u00a0\u00bb\u00a0\u00bb]Les r\u00e9sultats de l’\u00e9tude ont \u00e9t\u00e9 publi\u00e9s<\/a> dans la revue Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (ALSFD)<\/em> et repr\u00e9sentent le premier essai positif de phase 3 d’un inhibiteur de la tyrosine kinase dans la SLA.<\/p>\n

Une analyse de survie a concern\u00e9 tous les patients initialement recrut\u00e9s dans l’\u00e9tude AB10015 pendant une dur\u00e9e moyenne de 75 mois \u00e0 partir de la date du diagnostic. Chez les patients atteints de SLA dont la s\u00e9v\u00e9rit\u00e9 de la maladie \u00e9tait l\u00e9g\u00e8re ou mod\u00e9r\u00e9e au moment de l\u2019inclusion, il a \u00e9t\u00e9 observ\u00e9 que le traitement avec le masitinib \u00e0 la dose de 4,5 mg\/kg\/jour en association au riluzole prolongeait la survie de 25 mois par rapport aux patients trait\u00e9s par le riluzole seul, avec une r\u00e9duction du risque de d\u00e9c\u00e8s de 44%. Les personnes atteintes de SLA l\u00e9g\u00e8re ou mod\u00e9r\u00e9e correspondent \u00e9troitement \u00e0 la population de patients recrut\u00e9s dans l’\u00e9tude confirmatoire de phase 3, AB19001. Ces nouvelles donn\u00e9es de survie ont \u00e9t\u00e9 publi\u00e9es<\/a> dans la revue examin\u00e9e par des pairs Therapeutic Advances in Neurological Disorders<\/em>).<\/p>\n

Enfin, des analyses suppl\u00e9mentaires ont montr\u00e9 qu’il existe un b\u00e9n\u00e9fice clairement accru dans le sous-groupe appel\u00e9 \u201cSLA avant toute perte de fonction \u00bb (c’est-\u00e0-dire excluant les patients avec un score ALSFRS-R de 0 dans l’un des 12 composants du score). En effet, un b\u00e9n\u00e9fice significatif de + 12 mois en termes de survie (p = 0,0192) a \u00e9t\u00e9 observ\u00e9 dans ce sous-groupe.[\/vc_column_text]

<\/span>\u00c9tude confirmatoire de phase 3 avec le masitinib dans la Scl\u00e9rose Lat\u00e9rale Amyotrophique<\/span><\/div><\/div>
<\/div>[vc_column_text css=\u00a0\u00bb\u00a0\u00bb]Une nouvelle \u00e9tude confirmatoire de phase 3, simplifi\u00e9e pour le recrutement et ciblant les meilleurs r\u00e9pondeurs au masitinib, sera initi\u00e9e conform\u00e9ment aux recommandations de la FDA et de l’EMA. Le design de l\u2019\u00e9tude confirmatoire de Phase 3 a r\u00e9cemment \u00e9t\u00e9 approuv\u00e9 par la FDA et l’EMA (syt\u00e8me CTIS, \u00e9tape 1).<\/p>\n

 [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text][\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row css=\u00a0\u00bb.vc_custom_1633514202311{background-color: #00477a !important;border: 10px solid #00477a !important;border-radius: 10px !important;}\u00a0\u00bb][vc_column css=\u00a0\u00bb.vc_custom_1633514590586{padding-top: 20px !important;}\u00a0\u00bb][vc_column_text css=\u00a0\u00bb.vc_custom_1633514499321{margin-bottom: 20px !important;}\u00a0\u00bb] Si vous souhaitez participer \u00e0 l\u2019\u00e9tude en cours, veuillez nous contacter \u00e0 clinical@ab-science.com\u200b [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]La scl\u00e9rose lat\u00e9rale amyotrophique (SLA) est une maladie neurod\u00e9g\u00e9n\u00e9rative rare et potentiellement mortelle, caract\u00e9ris\u00e9e par une paralysie musculaire progressive refl\u00e9tant une d\u00e9g\u00e9n\u00e9rescence des neurones moteurs. La…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":3763,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3727","page","type-page","status-publish","hentry","description-off"],"yoast_head":"\nScl\u00e9rose Lat\u00e9rale Amyotrophique – AB Science<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/sclerose-laterale-amyotrophique\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Scl\u00e9rose Lat\u00e9rale Amyotrophique\" \/>\n<meta property=\"og:description\" content=\"[vc_row css=\u00a0\u00bb.vc_custom_1633514202311{background-color: #00477a !important;border: 10px solid #00477a !important;border-radius: 10px !important;}\u00a0\u00bb][vc_column css=\u00a0\u00bb.vc_custom_1633514590586{padding-top: 20px !important;}\u00a0\u00bb][vc_column_text css=\u00a0\u00bb.vc_custom_1633514499321{margin-bottom: 20px !important;}\u00a0\u00bb] Si vous souhaitez participer \u00e0 l\u2019\u00e9tude en cours, veuillez nous contacter \u00e0 clinical@ab-science.com\u200b [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]La scl\u00e9rose lat\u00e9rale amyotrophique (SLA) est une maladie neurod\u00e9g\u00e9n\u00e9rative rare et potentiellement mortelle, caract\u00e9ris\u00e9e par une paralysie musculaire progressive refl\u00e9tant une d\u00e9g\u00e9n\u00e9rescence des neurones moteurs. La…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/sclerose-laterale-amyotrophique\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-21T13:11:52+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/sclerose-laterale-amyotrophique\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/sclerose-laterale-amyotrophique\\\/\",\"name\":\"Scl\u00e9rose Lat\u00e9rale Amyotrophique – AB Science\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-10-01T10:43:29+00:00\",\"dateModified\":\"2025-05-21T13:11:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/sclerose-laterale-amyotrophique\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/sclerose-laterale-amyotrophique\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/sclerose-laterale-amyotrophique\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pipeline\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Masitinib\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-overview\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Scl\u00e9rose Lat\u00e9rale Amyotrophique\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Scl\u00e9rose Lat\u00e9rale Amyotrophique – AB Science","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/sclerose-laterale-amyotrophique\/","og_locale":"fr_FR","og_type":"article","og_title":"Scl\u00e9rose Lat\u00e9rale Amyotrophique","og_description":"[vc_row css=\u00a0\u00bb.vc_custom_1633514202311{background-color: #00477a !important;border: 10px solid #00477a !important;border-radius: 10px !important;}\u00a0\u00bb][vc_column css=\u00a0\u00bb.vc_custom_1633514590586{padding-top: 20px !important;}\u00a0\u00bb][vc_column_text css=\u00a0\u00bb.vc_custom_1633514499321{margin-bottom: 20px !important;}\u00a0\u00bb] Si vous souhaitez participer \u00e0 l\u2019\u00e9tude en cours, veuillez nous contacter \u00e0 clinical@ab-science.com\u200b [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]La scl\u00e9rose lat\u00e9rale amyotrophique (SLA) est une maladie neurod\u00e9g\u00e9n\u00e9rative rare et potentiellement mortelle, caract\u00e9ris\u00e9e par une paralysie musculaire progressive refl\u00e9tant une d\u00e9g\u00e9n\u00e9rescence des neurones moteurs. La…","og_url":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/sclerose-laterale-amyotrophique\/","og_site_name":"AB Science","article_modified_time":"2025-05-21T13:11:52+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/sclerose-laterale-amyotrophique\/","url":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/sclerose-laterale-amyotrophique\/","name":"Scl\u00e9rose Lat\u00e9rale Amyotrophique – AB Science","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/#website"},"datePublished":"2020-10-01T10:43:29+00:00","dateModified":"2025-05-21T13:11:52+00:00","breadcrumb":{"@id":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/sclerose-laterale-amyotrophique\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/sclerose-laterale-amyotrophique\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/sclerose-laterale-amyotrophique\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ab-science.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Pipeline","item":"https:\/\/www.ab-science.com\/fr\/pipeline\/"},{"@type":"ListItem","position":3,"name":"Masitinib","item":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-overview\/"},{"@type":"ListItem","position":4,"name":"Scl\u00e9rose Lat\u00e9rale Amyotrophique"}]},{"@type":"WebSite","@id":"https:\/\/www.ab-science.com\/fr\/#website","url":"https:\/\/www.ab-science.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ab-science.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ab-science.com\/fr\/#organization","name":"AB Science","url":"https:\/\/www.ab-science.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/3727","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/comments?post=3727"}],"version-history":[{"count":0,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/3727\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/3763"}],"wp:attachment":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/media?parent=3727"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}